OTHER INFORMATION
−Removed: During the six months ended June 30, 2024, no director or officer of the Company adopted or terminated a “Rule 10b5-1
+Added: During the three
+Added: months ended September 30, 2024, no director or officer of the Company adopted or terminated a “Rule 10b5-1
trading arrangement” or “non-Rule
19 unchanged sentences
333-264597) filed with the SEC on May 10, 2022)
−Removed: Promissory Note, dated April 8, 2024, issued by Bellevue Life Sciences Acquisition Corp.
−Removed: to Bellevue Global Life Sciences Investors LLC (Incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K (File No.
−Removed: 001-41390) filed with the SEC on April 11, 2024)
−Removed: Promissory Note, dated April 17, 2024, issued by Bellevue Life Sciences Acquisition Corp.
−Removed: to Bellevue Global Life Sciences Investors LLC (Incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K (File No.
−Removed: 001-41390) filed with the SEC on April 22, 2024)
−Removed: Promissory Note, dated May 14, 2024, issued by Bellevue Life Sciences Acquisition Corp.
+Added: Promissory Note, dated July 11, 2024, issued by Bellevue Life Sciences Acquisition Corp.
to Bellevue Global Life Sciences Investors, LLC (Incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K (File No.
−Removed: 001-41390) filed with the SEC on May 14, 2024)
+Added: 001-41390) filed with the SEC on July 16, 2024)
+Added: Amendment to Promissory Note, dated September 20, 2024, issued by Bellevue Life Sciences Acquisition Corp.
+Added: to Jun Chul Whang (Incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K (File No.
+Added: 001-41390) filed with the SEC on September 24, 2024)
+Added: Amendment to Promissory Note, dated September 20, 2024, issued by Bellevue Life Sciences Acquisition Corp.
+Added: to Josh Pan (Incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K (File No.
+Added: 001-41390) filed with the SEC on September 24, 2024)
Certification of Principal Executive Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15(d)-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 **
17 unchanged sentences
BELLEVUE LIFE SCIENCES ACQUISITION CORP.
−Removed: August 19, 2024
+Added: November 14, 2024
/s/ Kuk Hyoun Hwang
2 unchanged sentences
(Principal Executive Officer)
−Removed: August 19, 2024
+Added: November 14, 2024
Chief Financial Officer
1 unchanged sentence
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.